Brand-name, generics firms fight over bulk drug supplies

11/11/2009 | Wall Street Journal, The

Complaints from generic-drug firms prompted the Federal Trade Commission to look into practices of brand-name companies that refuse to supply bulk quantities of medicines that can aid the development of copycat drugs. The FTC did not say whether it is investigating. Meanwhile, Dr. Reddy's Laboratories filed a petition with the FDA to clarify whether brand-name manufacturers can hide behind a drug-safety program that restricts the distribution of certain treatments to prevent misuse.

View Full Article in:

Wall Street Journal, The